WallStreetZenWallStreetZen

NASDAQ: BBIO
Bridgebio Pharma Inc Stock

$24.98-0.26 (-1.03%)
Updated Apr 17, 2024
BBIO Price
$24.98
Fair Value Price
$25.10
Market Cap
$4.39B
52 Week Low
$12.75
52 Week High
$44.32
P/E
-6.32x
P/B
-3.24x
P/S
706.43x
PEG
N/A
Dividend Yield
N/A
Revenue
$9.30M
Earnings
-$643.20M
Gross Margin
73.7%
Operating Margin
-6,040.13%
Profit Margin
-6,913.9%
Debt to Equity
-1.4
Operating Cash Flow
-$528M
Beta
1.41
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A

BBIO Overview

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BBIO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

BBIO ($24.98) is undervalued by 0.49% relative to our estimate of its Fair Value price of $25.10 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
BBIO ($24.98) is not significantly undervalued (0.49%) relative to our estimate of its Fair Value price of $25.10 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BBIO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BBIO due diligence checks available for Premium users.

Be the first to know about important BBIO news, forecast changes, insider trades & much more!

BBIO News

Valuation

BBIO fair value

Fair Value of BBIO stock based on Discounted Cash Flow (DCF)
Price
$24.98
Fair Value
$25.10
Undervalued by
0.49%
BBIO ($24.98) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BBIO ($24.98) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BBIO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

BBIO price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-6.32x
Industry
15.83x
Market
41.64x

BBIO price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-3.24x
Industry
5.83x

BBIO's financial health

Profit margin

Revenue
$1.7M
Net Income
-$168.1M
Profit Margin
-9,636%
BBIO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BBIO's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$546.4M
Liabilities
$1.9B
Debt to equity
-1.4
BBIO's short-term assets ($477.59M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BBIO's long-term liabilities ($1.75B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BBIO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BBIO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$124.8M
Investing
-$66.0k
Financing
-$4.5M
BBIO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

BBIO vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
BBIO$4.39B-1.03%-6.32x-3.24x
CRSP$4.46B-4.14%-28.64x2.37x
MDGL$4.54B-1.99%-11.42x11.21x
ALPN$4.23B-0.06%-100.72x12.88x
IMVT$4.13B-6.48%-15.54x6.08x

Bridgebio Pharma Stock FAQ

What is Bridgebio Pharma's quote symbol?

(NASDAQ: BBIO) Bridgebio Pharma trades on the NASDAQ under the ticker symbol BBIO. Bridgebio Pharma stock quotes can also be displayed as NASDAQ: BBIO.

If you're new to stock investing, here's how to buy Bridgebio Pharma stock.

What is the 52 week high and low for Bridgebio Pharma (NASDAQ: BBIO)?

(NASDAQ: BBIO) Bridgebio Pharma's 52-week high was $44.32, and its 52-week low was $12.75. It is currently -43.64% from its 52-week high and 95.92% from its 52-week low.

How much is Bridgebio Pharma stock worth today?

(NASDAQ: BBIO) Bridgebio Pharma currently has 175,831,536 outstanding shares. With Bridgebio Pharma stock trading at $24.98 per share, the total value of Bridgebio Pharma stock (market capitalization) is $4.39B.

Bridgebio Pharma stock was originally listed at a price of $27.55 in Jun 27, 2019. If you had invested in Bridgebio Pharma stock at $27.55, your return over the last 4 years would have been -9.33%, for an annualized return of -2.42% (not including any dividends or dividend reinvestments).

How much is Bridgebio Pharma's stock price per share?

(NASDAQ: BBIO) Bridgebio Pharma stock price per share is $24.98 today (as of Apr 17, 2024).

What is Bridgebio Pharma's Market Cap?

(NASDAQ: BBIO) Bridgebio Pharma's market cap is $4.39B, as of Apr 18, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Bridgebio Pharma's market cap is calculated by multiplying BBIO's current stock price of $24.98 by BBIO's total outstanding shares of 175,831,536.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.